Bioventus Inc. (BVS)

Market Cap	283.94M
Revenue (ttm)	512.35M
Net Income (ttm)	-156.23M
Shares Out	63.38M
EPS (ttm)	-2.49
PE Ratio	n/a
Forward PE	29.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	129,705
Open	4.550
Previous Close	4.550
Day's Range	4.440 - 4.620
52-Week Range	0.860 - 6.080
Beta	0.50
Analysts	Strong Buy
Price Target	8.00 (+78.57%)
Earnings Date	May 9, 2024

About BVS

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that in...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 2021
• Employees: 970
• Stock Exchange: NASDAQ
• Ticker Symbol: BVS

Financial Performance

In 2023, Bioventus's revenue was $512.35 million, an increase of 0.04% compared to the previous year's $512.12 million. Losses were -$156.23 million, -1.56% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for BVS stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 78.57% from the latest price.

Price Target

$8.0

(78.57% upside)

Analyst Consensus: Strong Buy